Nuformix Plc (DE:1RT)
FRANKFURT:1RT
1RT Stock Chart & Stats
€0.01
>-€0.01(-23.08%)
At close: 4:00 PM EST
€0.01
>-€0.01(-23.08%)
Day’s Range― - ―
52-Week Range€0.02 - €0.02
Previous CloseN/A
Volume0.00
Average Volume (3M)90.00K
Market Cap
€5.09M
Enterprise Value€3.39M
Total Cash (Recent Filing)€930.28K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-1.00
Next Earnings
Feb 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,609,750,000
10 Day Avg. Volume90,000
30 Day Avg. Volume90,000
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-6.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Cocrystal Technology PlatformA proprietary cocrystal platform is a durable technical asset that can improve API stability and bioavailability, enabling reformulations and lifecycle extensions. Over months this supports licensing, partnering and differentiated product candidates that can generate non-linear long-term revenue streams if clinical translation succeeds.
Debt-free Capital StructureZero reported debt across recent years materially reduces financial fixed-cost burden and downside risk. This structural flexibility improves the company's ability to raise equity or grants for R&D, shields it from interest shocks, and extends runway relative to a leveraged peer while development milestones are pursued.
Focused Therapeutic Niche (fibrotic Diseases)A concentrated focus on fibrotic diseases targets high unmet medical need and well-defined regulatory pathways, which can allow efficient allocation of limited R&D resources. Specialization boosts technical expertise, enhances credibility with partners and payors, and can create a clearer route to meaningful clinical value over a multi-quarter horizon.
Bears Say
No Recent RevenueAbsence of revenue for multiple years indicates the company has not commercialised products and remains pre-revenue. This structural shortfall lengthens dependency on external funding, means product-market fit and pricing remain unproven, and increases execution risk for translating the platform into sustainable, recurring income.
Persistent Negative Free Cash FlowConsecutive negative operating and free cash flows show ongoing cash burn and inconsistent cash discipline. Over several quarters this necessitates external financing or dilution, constrains multi-year trial funding, and can divert management focus from product development to fundraising, impairing long-term execution.
Shrinking Equity And Asset BaseA materially reduced equity and asset base signals accumulated losses and a smaller financial buffer against setbacks. This structural fragility limits strategic optionality, weakens negotiating power with partners or vendors, and raises solvency and continuity risk if losses persist without commensurate capital injections.
Nuformix Plc News
1RT FAQ
What was Nuformix Plc’s price range in the past 12 months?
Nuformix Plc lowest stock price was €0.02 and its highest was €0.02 in the past 12 months.
What is Nuformix Plc’s market cap?
Nuformix Plc’s market cap is €5.09M.
When is Nuformix Plc’s upcoming earnings report date?
Nuformix Plc’s upcoming earnings report date is Feb 03, 2027 which is in 240 days.
How were Nuformix Plc’s earnings last quarter?
Nuformix Plc released its earnings results on May 28, 2026. The company reported €0 earnings per share for the quarter, the consensus estimate of N/A by €0.
Is Nuformix Plc overvalued?
According to Wall Street analysts Nuformix Plc’s price is currently Overvalued.
Does Nuformix Plc pay dividends?
Nuformix Plc does not currently pay dividends.
What is Nuformix Plc’s EPS estimate?
Nuformix Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuformix Plc have?
Nuformix Plc has 2,609,750,000 shares outstanding.
What happened to Nuformix Plc’s price movement after its last earnings report?
Nuformix Plc reported an EPS of €0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Nuformix Plc?
Currently, no hedge funds are holding shares in DE:1RT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuformix Plc
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Evgen Pharma
―
Futura Medical
―
ImmuPharma
―
OptiBiotix Health
―
HemoGenyx Pharmaceuticals Plc
―